

ASX RELEASE**9 March 2022****ASX: NVU**

Nanoshield Accepted as Medical Device in the UK

Highlights:

- **Nanoshield™ Antiviral Film product accepted as Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA).**
- **As announced 8 March 2022, Nanoveu submitted the filing to the MHRA with approval received in under 24 hours.**
- **Nanoveu can now market the Nanoshield™ product for a range of medical and non-medical applications in the United Kingdom.**
- **Nanoshield™ is the only self-disinfecting coating registered as a Class 1 medical device in the UK.**

Nanoveu Limited (**ASX:NVU**) ("**Nanoveu**" or the "**Company**") is pleased to announce that the Company has received approval for the registration of its Nanoshield™ Film line as a Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) for the UKCA (UK Conformity Assessed) Mark.

Nanoveu can now market the Nanoshield™ product for a range of medical and non-medical applications in the United Kingdom.

Nanoveu's Managing Director and CEO, Alfred Chong, commented: *"We are very pleased to have received such a timely acceptance for our Nanoshield™ Antiviral Film as a Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA). We look forward to advancing our entry further beyond the UK market and into the EU over the coming months."*

As announced on 8 March 2022, the Company submitted the filing to the MHRA, with approval for the application being received in under 24 hours.

Nanoshield is intended to be applied to high touch surfaces of medical devices including, but not limited to, display screens of defibrillators and imaging devices to provide long lasting, continuous disinfection, reducing user-to-user touch cross-contamination thus assisting in prevention of disease. The applications within the Medical context can also include touch screens, handrails, trolleys, wheel chair handles and just about any high touch point.

- Ends -

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Alfred Chong
Managing Director and CEO

t: +65 6557 0155

e: info@nanoveu.com

For media / investor enquiries, please contact:

Jane Morgan
Investor Relations

t: 0405 555 618

e: info@janemorganmanagement.com.au

About Nanoveu Limited

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

Nanoshield - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.